BIOMAT Database Logo BIOMAT Database Logo

Sevelamer versus calcium-based phosphate binders in chronic kidney disease: what should we conclude from the evidence to date? 2009

David W Johnson

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D011073 Polyamines Amine compounds that consist of carbon chains or rings containing two or more primary amino groups. Polyamine
D002614 Chelating Agents Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. Chelating Agent,Chelator,Complexons,Metal Antagonists,Chelators,Metal Chelating Agents,Agent, Chelating,Agents, Chelating,Agents, Metal Chelating,Antagonists, Metal,Chelating Agents, Metal
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069603 Sevelamer A polymeric amine that binds phosphate and is used to treat HYPERPHOSPHATEMIA in patients with kidney disease. GT335-012,RenaGel,Sevelamer Carbonate,Sevelamer Hydrochloride,Carbonate, Sevelamer,GT335 012,GT335012,Hydrochloride, Sevelamer

Related Publications

David W Johnson
Sevelamer versus calcium-based phosphate binders for chronic kidney disease.
May 2017, Medwave,
David W Johnson
Phosphate binders in chronic kidney disease. When should we start, what should we prescribe?
November 2012, Expert opinion on pharmacotherapy,
David W Johnson
[Phosphate binders in chronic kidney disease: the positions of sevelamer].
January 2013, Terapevticheskii arkhiv,
David W Johnson
Calcium-based phosphate binders and chronic kidney disease.
January 2014, Lancet (London, England),
David W Johnson
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
March 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,
David W Johnson
Chronic kidney disease: calcium-based versus non-calcium-based phosphate binders: effect on mortality in patients with CKD.
September 2013, Nature reviews. Nephrology,
David W Johnson
The role of calcium and non calcium-based phosphate binders in chronic kidney disease.
March 2017, Nephrology (Carlton, Vic.),
David W Johnson
Phosphate binders in moderate chronic kidney disease: where do we stand?
January 2013, Journal of nephrology,
David W Johnson
The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis.
October 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
David W Johnson
Cardiovascular calcification progression -- a comparison of sevelamer and calcium-based phosphate binders.
January 2005, Blood purification,
Copied contents to your clipboard!